COVID-19-Associated Mucormycosis: An Opportunistic Fungal Infection. A Case Series and Review
- PMID: 35533833
- PMCID: PMC9075983
- DOI: 10.1016/j.ijid.2022.05.005
COVID-19-Associated Mucormycosis: An Opportunistic Fungal Infection. A Case Series and Review
Abstract
Background: A surge in COVID-19-associated mucormycosis cases has been observed during the second wave of COVID-19 in summer of 2021. Most cases were reported from India. The Delta variant (B.1.617.2) was the most common variant circulating at that time. Mucormycosis is an opportunistic angioinvasive fungal infection with high morbidity and mortality.
Methods: We present 10 cases of COVID-19-associated rhino-orbital and rhino-orbital-cerebral mucormycosis managed in a secondary hospital in Oman.
Results: The median time for developing mucormycosis was two weeks after COVID-19 diagnosis. All patients were newly diagnosed or already known to have poorly controlled diabetes mellitus. Five patients received corticosteroid therapy for COVID-19. Three patients had severe COVID-19 and died of severe acute respiratory distress syndrome and septic shock. Another three patients died of advanced mucormycosis and cerebral involvement. Despite aggressive medical and surgical intervention, the mortality rate was 60% (6/10).
Conclusion: Mucormycosis is an aggressive opportunistic infection with high morbidity and mortality that requires prompt recognition and urgent intervention. Uncontrolled blood sugar, the use of corticosteroids, and immune dysfunction due to COVID-19 are all important risk factors for development of mucormycosis. Worse outcomes are associated with poor glycemic control despite aggressive medical and surgical interventions.
Keywords: COVID-19 associated mucormycosis; COVID-19 variants; Invasive mold infections; Mucorales; Rhino-orbital-cerebral mucormycosis; Rhizopus oryzae.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declarations of competing interest The authors have no competing interests to declare.
Figures

Similar articles
-
Is mucormycosis the end? A comprehensive management of orbit in COVID associated rhino-orbital-cerebral mucormycosis: preserving the salvageable.Eur Arch Otorhinolaryngol. 2023 Feb;280(2):819-827. doi: 10.1007/s00405-022-07620-3. Epub 2022 Sep 2. Eur Arch Otorhinolaryngol. 2023. PMID: 36053359 Free PMC article.
-
Rhino-Orbital Cerebral Mucormycosis in Non-Diabetic Patients with COVID-19.R I Med J (2013). 2021 Oct 1;104(8):19-21. R I Med J (2013). 2021. PMID: 34582509
-
First report of COVID-19-associated rhino-orbito-cerebral mucormycosis in pediatric patients with type 1 diabetes mellitus.J Mycol Med. 2021 Dec;31(4):101203. doi: 10.1016/j.mycmed.2021.101203. Epub 2021 Sep 4. J Mycol Med. 2021. PMID: 34517273 Free PMC article.
-
Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review.Indian J Pharmacol. 2021 Jul-Aug;53(4):317-327. doi: 10.4103/ijp.ijp_419_21. Indian J Pharmacol. 2021. PMID: 34414911 Free PMC article.
-
COVID-19-associated rhino-orbital-cerebral mucormycosis: A systematic review, meta-analysis, and meta-regression analysis.Indian J Pharmacol. 2021 Nov-Dec;53(6):499-510. doi: 10.4103/ijp.ijp_839_21. Indian J Pharmacol. 2021. PMID: 34975140 Free PMC article.
Cited by
-
Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.Curr Med Mycol. 2023 Mar;9(1):44-55. doi: 10.18502/cmm.2023.345032.1400. Curr Med Mycol. 2023. PMID: 37867589 Free PMC article. Review.
-
Mucormycosis and Its Upsurge During COVID-19 Epidemic: An Updated Review.Curr Microbiol. 2023 Aug 17;80(10):322. doi: 10.1007/s00284-023-03430-w. Curr Microbiol. 2023. PMID: 37592083 Review.
-
COVID-19, mucormycosis, and the cow: Damned lies!Indian J Med Microbiol. 2023 Jul-Aug;44:100382. doi: 10.1016/j.ijmmb.2023.100382. Epub 2023 May 24. Indian J Med Microbiol. 2023. PMID: 37356841 Free PMC article. No abstract available.
-
Missed Opportunities for Antifungal Stewardship during the COVID-19 Era.Antibiotics (Basel). 2023 Aug 23;12(9):1352. doi: 10.3390/antibiotics12091352. Antibiotics (Basel). 2023. PMID: 37760649 Free PMC article.
-
A Tragic Tale of Mucormycosis and COVID-19: An Observational Study to Identify Predisposing Risk Factors and Outcomes in a Tertiary Care Centre in Central India.Cureus. 2025 May 4;17(5):e83479. doi: 10.7759/cureus.83479. eCollection 2025 May. Cureus. 2025. PMID: 40470445 Free PMC article.
References
-
- Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative for the European Confederation of medical mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:E405–E421. - PMC - PubMed
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical